Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LPTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-3.20
vs -0.90
Q2.23
N/A
-0.91
vs -1.50
Q3.23
N/A
-0.51
vs -1.30
Q4.23
N/A
-0.46
vs -1.10
Q1.24
N/A
-0.51
vs -3.20
Q2.24
N/A
-0.52
vs -0.91
Q3.24
N/A
-0.44
vs -0.51
Q4.24
N/A
-0.37
vs -0.46
Q1.25
N/A
-0.38
vs -0.51
Q2.25
N/A
-0.35
vs -0.52
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
634K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 634K
Q1.25
NA
5.5M vs NA
Q2.25
NA
7.6M vs NA
Return on Equity
QoQ
Q1.23
-145%
-1.45
vs -0.21
Q2.23
-16%
-0.16
vs -1.45
Q3.23
-19%
-0.19
vs -0.16
Q4.23
-21%
-0.21
vs -0.19
Q1.24
-29%
-0.29
vs -0.21
Q2.24
-31%
-0.31
vs -0.29
Q3.24
-37%
-0.37
vs -0.31
Q4.24
-44%
-0.44
vs -0.37
Institutionnal Ownership
QoQ
Q1.23
60
60
vs 61
-2%
Q2.23
40
40
vs 60
-33%
Q3.23
44
44
vs 40
10%
Q4.23
48
48
vs 44
9%
Q1.24
46
46
vs 48
-4%
Q2.24
48
48
vs 46
4%
Q3.24
48
48
vs 48
NA
Q4.24
60
60
vs 48
25%
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
seekingalpha.com
13 hours ago
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01Â ( 1.73%)
Relative Strenght
2
Volume Buzz
-87%
Earning Acce
Yes
Dist 52w H.
92%Quote Panel
Key Metrics
Relative Strength
LPTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2025-Revenue
-241%2025-EPS
143%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Rodman & Renshaw
initialisePrevious: Not converted
2024-06-28
Now: Buy
